A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma (BAY 80-6946 /19176)

This Study is
No Longer Enrolling

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 17-1495

More information available at ClinicalTrials.gov: NCT03458728

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers